减少小儿肿瘤患者非中性粒细胞减少热的经验性抗生素使用:一项单中心质量改善倡议。

IF 1.2 4区 医学 Q4 HEMATOLOGY
Pediatric Hematology and Oncology Pub Date : 2025-05-01 Epub Date: 2025-05-07 DOI:10.1080/08880018.2025.2498664
Alexandra Satty, Jessica Stiefel, Audrey Mauguen, Zahra Hudda, Madhavi Lakkaraja, Gabriela Llaurador, Mauricio Rendon Bernot, Susan K Seo, Julia Glade Bender, Maria Luisa Sulis, Farid Boulad, James S, Killinger
{"title":"减少小儿肿瘤患者非中性粒细胞减少热的经验性抗生素使用:一项单中心质量改善倡议。","authors":"Alexandra Satty, Jessica Stiefel, Audrey Mauguen, Zahra Hudda, Madhavi Lakkaraja, Gabriela Llaurador, Mauricio Rendon Bernot, Susan K Seo, Julia Glade Bender, Maria Luisa Sulis, Farid Boulad, James S, Killinger","doi":"10.1080/08880018.2025.2498664","DOIUrl":null,"url":null,"abstract":"<p><p>The management of non-neutropenic fever in pediatric oncology varies widely, with many providers choosing to administer empiric antibiotics. We conducted a quality improvement intervention seeking to decrease empiric antibiotic administration in pediatric oncology patients with a central venous catheter presenting in the outpatient setting with non-neutropenic fever assessed to be low-risk for bacteremia. Over a 1-year period, empiric antibiotics were administered at the index visit in 9.6% of episodes, compared with 97% prior to the intervention. In patients not receiving empiric antibiotics, the bacteremia rate was 2.3% and composite event rate 5.1%, similar to pre-intervention baseline. These data suggest that empiric antibiotics can be withheld in low-risk patients with non-neutropenic fever.</p>","PeriodicalId":19746,"journal":{"name":"Pediatric Hematology and Oncology","volume":" ","pages":"242-249"},"PeriodicalIF":1.2000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Reducing empiric antibiotic administration in pediatric oncology patients with non-neutropenic fever: a single-center quality improvement initiative.\",\"authors\":\"Alexandra Satty, Jessica Stiefel, Audrey Mauguen, Zahra Hudda, Madhavi Lakkaraja, Gabriela Llaurador, Mauricio Rendon Bernot, Susan K Seo, Julia Glade Bender, Maria Luisa Sulis, Farid Boulad, James S, Killinger\",\"doi\":\"10.1080/08880018.2025.2498664\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The management of non-neutropenic fever in pediatric oncology varies widely, with many providers choosing to administer empiric antibiotics. We conducted a quality improvement intervention seeking to decrease empiric antibiotic administration in pediatric oncology patients with a central venous catheter presenting in the outpatient setting with non-neutropenic fever assessed to be low-risk for bacteremia. Over a 1-year period, empiric antibiotics were administered at the index visit in 9.6% of episodes, compared with 97% prior to the intervention. In patients not receiving empiric antibiotics, the bacteremia rate was 2.3% and composite event rate 5.1%, similar to pre-intervention baseline. These data suggest that empiric antibiotics can be withheld in low-risk patients with non-neutropenic fever.</p>\",\"PeriodicalId\":19746,\"journal\":{\"name\":\"Pediatric Hematology and Oncology\",\"volume\":\" \",\"pages\":\"242-249\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Hematology and Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/08880018.2025.2498664\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Hematology and Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08880018.2025.2498664","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/7 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

小儿肿瘤学非中性粒细胞减少热的管理差异很大,许多提供者选择管理经验性抗生素。我们进行了一项质量改进干预,旨在减少门诊有中心静脉导管的儿科肿瘤患者的经经性抗生素给药,这些患者被评估为低风险的菌血症。在1年的时间里,9.6%的病例在指标就诊时使用了经验性抗生素,而干预前这一比例为97%。在未接受经验性抗生素治疗的患者中,菌血症率为2.3%,复合事件率为5.1%,与干预前基线相似。这些数据表明,经验性抗生素可以在低风险的非中性粒细胞减少热患者中保留。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Reducing empiric antibiotic administration in pediatric oncology patients with non-neutropenic fever: a single-center quality improvement initiative.

The management of non-neutropenic fever in pediatric oncology varies widely, with many providers choosing to administer empiric antibiotics. We conducted a quality improvement intervention seeking to decrease empiric antibiotic administration in pediatric oncology patients with a central venous catheter presenting in the outpatient setting with non-neutropenic fever assessed to be low-risk for bacteremia. Over a 1-year period, empiric antibiotics were administered at the index visit in 9.6% of episodes, compared with 97% prior to the intervention. In patients not receiving empiric antibiotics, the bacteremia rate was 2.3% and composite event rate 5.1%, similar to pre-intervention baseline. These data suggest that empiric antibiotics can be withheld in low-risk patients with non-neutropenic fever.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.60
自引率
5.90%
发文量
71
审稿时长
6-12 weeks
期刊介绍: PHO: Pediatric Hematology and Oncology covers all aspects of research and patient management within the area of blood disorders and malignant diseases of childhood. Our goal is to make PHO: Pediatric Hematology and Oncology the premier journal for the international community of clinicians and scientists who together aim to define optimal therapeutic strategies for children and young adults with cancer and blood disorders. The journal supports articles that address research in diverse clinical settings, exceptional case studies/series that add novel insights into pathogenesis and/or clinical care, and reviews highlighting discoveries and challenges emerging from consortia and conferences. Clinical studies as well as basic and translational research reports regarding cancer pathogenesis, genetics, molecular diagnostics, pharmacology, stem cells, molecular targeting, cellular and immune therapies and transplantation are of interest. Papers with a focus on supportive care, late effects and on related ethical, legal, psychological, social, cultural, or historical aspects of these fields are also appreciated. Reviews on important developments in the field are welcome. Articles from scientists and clinicians across the international community of Pediatric Hematology and Oncology are considered for publication. The journal is not dependent on or connected with any organization or society. All submissions undergo rigorous peer review prior to publication. Our Editorial Board includes experts in Pediatric Hematology and Oncology representing a wide range of academic and geographic diversity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信